Skip to main content
. 2024 Nov 26;15:1471017. doi: 10.3389/fimmu.2024.1471017

Table 4.

Patient treatment-related adverse events.

Adverse Events Grade 1 Grade 2 Grade 3 Grade 4
Abdominal pain 13 (25.40%) 5 (9.80%) 2 (3.90%) 0 (0.00%)
Anorexia 27 (52.90%) 7 (13.70%) 6 (11.80%) 1 (1.90%)
Vomiting 17 (33.30%) 3 (5.90%) 5 (9.80%) 1 (1.90%)
Fever 6 (11.80%) 1 (1.90%) 1 (1.90%) 0 (0.00%)
Diarrhea 9 (17.60%) 3 (5.90%) 3 (5.90%) 0 (0.00%)
Leukopenia 14 (27.50%) 6 (11.80%) 5 (9.80%) 0 (0.00%)
Thrombocytopenia 22 (43.10%) 12 (23.50%) 5 (9.80%) 1 (1.90%)
Elevated transaminases 28 (54.90%) 6 (11.80%) 5 (9.80%) 1 (1.90%)
Elevated bilirubin 16 (31.40%) 5 (9.80%) 2 (3.90%) 0 (0.00%)
Renal insufficiency 5 (9.80%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Hypoproteinemia 9 (17.60%) 6 (11.80%) 3 (5.90%) 0 (0.00%)
Cholangitis 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Liver failure 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Catheter dislodgement 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Catheter thrombosis 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Hypertension 12 (23.50%) 5 (9.80%) 2 (3.90%) 0 (0.00%)
Gastrointestinal bleeding 0 (0.00%) 0 (0.00%) 0 (0.00%) 1 (1.90%)